Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage
biopharmaceutical company discovering and developing protein
therapeutics to treat diseases of the eye, today announced the issuance
of U.S. Patent No.
Given the rapidly evolving hepatitis C (HCV) treatment landscape in the
U.S., Bristol-Myers Squibb (NYSE:BMY) has decided that it will not
pursue U.S. Food and Drug Administration (FDA) approval of the dual
regimen of daclatasvir and asunaprevir for the treatment of HCV genotype
1b patients in the United States and has therefore withdrawn its new
drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor.
Crown Media Holdings, Inc. (NASDAQ:CRWN), owner and operator of Crown
Media Family Networks, home of Hallmark Channel and Hallmark Movies &
Mysteries, today announced it has changed the date of its third quarter
earnings conference call and webcast, originally scheduled for November
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and
Drug Administration (FDA) has accepted Cerus’ clinical protocol to make
the INTERCEPT Blood System for platelets available under an Expanded
Access Investigational Device Exemption (IDE) to regions in the United
States with outbreaks of Chikungunya and dengue virus.
Tallgrass Energy Partners, LP (NYSE: TEP) announced today that the board
of directors of its general partner declared a quarterly cash
distribution to partners of $0.41 per common unit for the third quarter
of 2014, or $1.64 on an annualized basis.
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “ Company ”) confirms that, as of the close of
business on October 6, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 452,488,239 ordinary shares, par
value US$0.20 per share (the “ Ordinary Shares ”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares is IE00B68SQD29.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.